Emerging Developments in the Treatment of Generalized Myasthenia Gravis

Target Audience
This activity is designed to meet the educational needs of neurologists and allied healthcare professionals who during their practice treat and/or manage patients with generalized myasthenia gravis (gMG) or who wish to gain advanced knowledge in diagnosis and management of patients with this disorder.

Program Overview
This activity will address the current treatment landscape as it compares to clinical trials in development focusing on FcRn modulation as a therapeutic target for myasthenia gravis (MG). We will review FcRn inhibitor therapeutic agents and discuss how these therapies may effectively change the management of patients with MG.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Compare the limitations of traditional therapies, including long-term effects and clinical challenges, to new and emerging treatment options for myasthenia gravis (MG).
Define FcRn inhibition and how promoting the degradation of IgG antibodies can improve patient outcomes in myasthenia gravis and other IgG mediated diseases.
Evaluate the efficacy and safety of emerging FcRn inhibitor agents and their application into clinical practice